Drug · DIN 02559617
BLENREP
SINGLE-USE VIAL
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since August 11, 2025; first marketed August 11, 2025.
- Drug Identification Number (DIN)
- 02559617
- Company (DIN owner)
- Glaxosmithkline IncMississauga, Ontario, Canada
- Schedule
- Schedule d; Prescription
- Dosage form
- Powder For Solution
- Route
- Intravenous
- Therapeutic class (ATC)
- Belantamab mafodotin L01FX15
- Class
- Human
- Record last updated
- August 13, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| BELANTAMAB MAFODOTIN | 70 MG | VIAL |
Notices of Compliance
Health Canada approvals that name this DIN.
- July 18, 2025: NOC 35724New Drug Submission (NDS)
Other DINs named BLENREP
- DIN 02559625 · Marketed